In addition to deciphering the tumor cells, efforts have been made to characterize the tumor immune microenvironment (TIME), improving the clinical benefit of immunotherapy, especially anti-PD-1/L1 and anti-CTLA4 antibodies [10, 11]; however, many patients still have poor outcomes [12, 13]. This evidence concerns the gene CTLA4 and neoplasm.